6533b7d8fe1ef96bd126ab4f

RESEARCH PRODUCT

Treatment Persistence and Safety of Apremilast in Psoriasis: Experience With 30 Patients in Routine Clinical Practice

B. De Unamuno BustosAntonio Sahuquillo-torralbaM. Rodríguez SernaE. Monte BoquetR. Botella Estrada

subject

medicine.medical_specialtyHistologybusiness.industryRetrospective cohort studyDermatologymedicine.diseaseDermatologyPathology and Forensic Medicinebody regions030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinemedicine.anatomical_structurePsoriasisScalpmedicineRoutine clinical practiceObservational studyApremilastbusinessAdverse effectSurvival analysis030215 immunologymedicine.drug

description

Apremilast is a phosphodiesterase-4 inhibitor taken orally. Little information about its use in routine clinical practice is available. We aimed to assess treatment safety and persistence rates in patients on apremilast for different forms of plaque psoriasis. This observational retrospective study included 30 patients with psoriasis who were treated with apremilast between January 2016 and December 2017 in our hospital. Twelve patients had palmar-plantar psoriasis, 8 had plaque psoriasis mainly on the scalp, and 10 had plaque psoriasis in other locations. The probable period of treatment persistence in patients in the 50th percentile was 18.5 months according to survival analysis of the series overall. Our experience suggests that apremilast is effective and safe for treating palmar-plantar psoriasis and plaques at other locations but not for treating scalp psoriasis. Adverse effects that compromise treatment occur in nearly two-thirds of the patients.

yearjournalcountryeditionlanguage
2020-06-01Actas Dermo-Sifiliográficas (English Edition)
https://doi.org/10.1016/j.adengl.2018.10.035